Growth Metrics

Cryo Cell International (CCEL) Non-Current Deffered Revenue (2016 - 2026)

Cryo Cell International's Non-Current Deffered Revenue history spans 17 years, with the latest figure at $52.1 million for Q1 2026.

  • Quarterly results put Non-Current Deffered Revenue at $52.1 million for Q1 2026, up 9.15% from a year ago — trailing twelve months through Feb 2026 was $52.1 million (up 9.15% YoY), and the annual figure for FY2025 was $51.0 million, up 9.49%.
  • Non-Current Deffered Revenue for Q1 2026 was $52.1 million at Cryo Cell International, up from $51.0 million in the prior quarter.
  • In the past five years, Non-Current Deffered Revenue ranged from a high of $52.1 million in Q1 2026 to a low of $32.2 million in Q1 2022.
  • The 5-year median for Non-Current Deffered Revenue is $42.6 million (2024), against an average of $42.4 million.
  • The sharpest move saw Non-Current Deffered Revenue grew 15.84% in 2023, then increased 9.15% in 2026.
  • Year by year, Non-Current Deffered Revenue stood at $36.0 million in 2022, then rose by 14.41% to $41.2 million in 2023, then increased by 13.04% to $46.6 million in 2024, then rose by 9.49% to $51.0 million in 2025, then grew by 2.21% to $52.1 million in 2026.
  • According to Business Quant data, Non-Current Deffered Revenue over the past three periods came in at $52.1 million, $51.0 million, and $49.8 million for Q1 2026, Q4 2025, and Q3 2025 respectively.